Clifford Swan Investment Counsel LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 239,641 shares of the company's stock after selling 3,346 shares during the period. Johnson & Johnson makes up 1.2% of Clifford Swan Investment Counsel LLC's investment portfolio, making the stock its 17th biggest holding. Clifford Swan Investment Counsel LLC's holdings in Johnson & Johnson were worth $34,657,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $213,000. Swedbank AB lifted its holdings in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares during the period. Donaldson Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 2.1% in the 3rd quarter. Donaldson Capital Management LLC now owns 343,944 shares of the company's stock valued at $55,740,000 after buying an additional 7,092 shares during the period. Cortland Associates Inc. MO lifted its holdings in shares of Johnson & Johnson by 21.2% in the 3rd quarter. Cortland Associates Inc. MO now owns 2,008 shares of the company's stock valued at $325,000 after buying an additional 351 shares during the period. Finally, Intact Investment Management Inc. lifted its holdings in shares of Johnson & Johnson by 23.3% in the 3rd quarter. Intact Investment Management Inc. now owns 91,809 shares of the company's stock valued at $14,879,000 after buying an additional 17,320 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
JNJ has been the subject of several research reports. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $171.33.
View Our Latest Research Report on JNJ
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.
Johnson & Johnson Trading Down 0.1 %
Shares of NYSE:JNJ traded down $0.20 during midday trading on Wednesday, reaching $165.22. The company's stock had a trading volume of 8,744,672 shares, compared to its average volume of 7,006,371. The firm has a market cap of $397.79 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The business has a 50 day moving average price of $152.11 and a 200 day moving average price of $156.19.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
